Book value and NAV increased in Q2 2025, with strong portfolio performance and a major new investment in Lead Biologics. Operating loss widened year-over-year due to a one-off write-down, but cash flow remained positive from divestments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.